Oxybutynin-associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment

Area of Science:

• Pharmacology
• Gerontology
• Neurology

Background:

• Anticholinergic medications, particularly oxybutynin, are widely prescribed for overactive bladder (OAB).
• Oxybutynin, a first-generation anticholinergic, is associated with cognitive impairments and potential dementia risk.
• Concerns are rising regarding the long-term cognitive effects of oxybutynin in OAB patients.

Purpose of the Study:

• To review current literature on the relationship between oxybutynin and cognitive function.
• To examine evidence from preclinical, clinical, and real-world studies.
• To discuss updated recommendations for OAB treatment strategies.

Main Methods:

• Literature review of preclinical, clinical, and real-world studies on oxybutynin and cognition.
• Analysis of oxybutynin's mechanism of action on muscarinic receptors.
• Examination of epidemiological data and clinical trial outcomes.

Main Results:

• Oxybutynin binds non-specifically to muscarinic receptors in the brain.
• Evidence indicates a link between oxybutynin use and adverse cognitive outcomes.
• Studies suggest a potential increased risk of dementia with oxybutynin exposure.

Conclusions:

• Oxybutynin's anticholinergic properties are associated with negative cognitive effects.
• Reduced use of oxybutynin and similar anticholinergics for OAB is recommended.
• Further research into safer OAB treatment alternatives is warranted.